Bylvay (Odevixibat)

Save 35% on brand name Bylvay.

Non-english packaging - English label and English insert included. Plan in advance - allow us 7 days to ship your medicine

European products manufactured at: Almac Pharma Services Limited Seagoe Industrial Estate Portadown, Craigavon County Armagh BT63 5UA United Kingdom (Northern Ireland)

Information about Bylvay (Odevixibat)

Bylvay (generic name: odevixibat) is an oral medication developed by Albireo Pharma. It is specifically designed to treat pruritus (itching) associated with progressive familial intrahepatic cholestasis (PFIC), a rare liver disease that affects bile flow. Odevixibat works by inhibiting the bile salt export pump (BSEP), a protein that regulates bile acid transport in the liver. By inhibiting BSEP, Bylvay reduces bile acid accumulation, improving liver function and alleviating the symptoms of PFIC, particularly the severe itching.

Product Highlights

• Bylvay is indicated for the treatment of pruritus (itching) in patients with progressive familial intrahepatic cholestasis (PFIC), a genetic liver disorder that results in impaired bile flow. PFIC can cause severe itching, liver damage, and ultimately liver failure if not treated.
• Bylvay is specifically used to manage the symptoms of itching associated with PFIC in children and adults.

Key Ingredient

• Odevixibat

Key Benefits

• Clinical trials have shown that Bylvay significantly reduces the severity of itching in patients with PFIC, which can greatly improve quality of life.
• By reducing bile acid accumulation, Bylvay helps protect the liver from further damage and supports its overall function.
• Bylvay comes in an oral suspension form, making it easier for patients, particularly children, to take compared to injectable treatments.
• Most patients tolerate Bylvay well, and it provides an important therapeutic option for managing PFIC, especially in patients who have limited treatment options.

Direction of Use

• The recommended starting dose for children with PFIC is 0.2 mg/kg once daily. This dose may be adjusted based on clinical response and tolerability, with a maximum recommended dose of 1.0 mg/kg/day.
• Bylvay is administered as an oral suspension. The dose should be measured with the provided syringe and taken once daily, preferably at the same time each day.
• It can be taken with or without food, but it's important to follow the dosing schedule recommended by the healthcare provider.

Safety Concerns

• As Bylvay affects bile acid regulation, liver function should be monitored regularly. Some patients may experience mild liver enzyme elevations during treatment, although serious liver problems are rare.
• Mild gastrointestinal issues such as diarrhea, nausea, and abdominal pain can occur in some patients. These side effects are generally manageable and resolve with time.
• In pediatric patients, especially infants, growth and development should be regularly monitored while using Bylvay. Although rare, potential concerns about delayed growth or other developmental issues may require attention.
• The long-term safety of Bylvay in the treatment of PFIC is still being studied. It is important to follow up with regular monitoring for side effects, especially with long-term use.

Avoid Bylvay (Odevixibat) If

• Patients who are allergic to odevixibat or any of the components in Bylvay should not take the medication.
• Bylvay is not recommended for patients with severe liver impairment, as the drug works on liver bile acid regulation. If liver function is severely compromised, alternative treatments may be necessary.
• There are no sufficient studies regarding the use of Bylvay during pregnancy. It should only be used if the potential benefits outweigh the risks, and only under the guidance of a healthcare provider.
• It is unknown whether odevixibat is excreted in human milk. Women who are breastfeeding should consult their healthcare provider before using this medication, especially if they are nursing infants with liver conditions.